Two medicines, side by side
Dexlansoprazole vs omeprazole
Dexlansoprazole and omeprazole are both labeled for acid reflux and ulcers. Drugs@FDA records approvals of dexlansoprazole since 2009 and of omeprazole since 1989. Pharmacies paid $3.71 per dexlansoprazole DR 60 mg capsule and $0.0295 per omeprazole DR 20 mg capsule (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. Omeprazole's other strengths are brand-only: $14.75 per pen (Prilosec DR 2.5 mg suspension). How each works, in its label's words: Dexlansoprazole, “Dexlansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the (H + , K + )-ATPase at the secretory …”; Omeprazole, “Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H + /K + ATPase enzyme system at the …”
Check it at the source: the dexlansoprazole FDA label on DailyMed (effective February 17, 2025); the omeprazole FDA label on DailyMed (effective April 22, 2024).
Highlights of the dexlansoprazole record
Dexlansoprazole (Dexilant) · label of February 17, 2025
Used for
From the label: indicationsDEXILANT is a proton pump inhibitor (PPI) indicated in patients 12 years of age and older for: Healing of all grades of erosive esophagitis (EE). ( 1.1 ) Maintenance of healed EE and relief of heartburn. ( 1.2 ) Treatment of symptomatic non-erosive gastroesophageal reflux disease (GERD). […]
On the market
- Earliest approval on file
- January 30, 2009
- Generic labelers
- 9 labelers
- Pharmacy cost
- $3.71 per capsule
Supply and safety
- Shortage
- No current entry
- Recalls
- 0
Highlights of the omeprazole record
Omeprazole (Prilosec) · label of April 22, 2024
Used for
From the label: indicationsOmeprazole is a proton pump inhibitor (PPI) indicated for the: Treatment of active duodenal ulcer in adults ( 1.1 ) Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults ( 1.2 ) Treatment of active benign gastric ulcer in adults ( 1.3 ) Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 1 year of age and older ( 1.4 ) Treatment of erosive esophagitis […]
On the market
- Earliest approval on file
- September 14, 1989
- Generic labelers
- 118 labelers
- Pharmacy cost
- $0.0295 per capsule
Supply and safety
- Shortage
- A presentation being discontinued
- Recalls
- 7
Source: FDA drug labels via openFDA (Dexlansoprazole label of February 17, 2025, Omeprazole label of April 22, 2024); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do dexlansoprazole and omeprazole differ on the record?
How each works, in its label's words: Dexlansoprazole, “Dexlansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the (H + , K + )-ATPase at the secretory …”; Omeprazole, “Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H + /K + ATPase enzyme system at the …”
Both are in FDA's class proton pump inhibitors.
Half-life, in each label's words: Dexlansoprazole, “NT Once Daily for 7 Days Dose C max (ng/mL) AUC tau (ng∙h/mL) CL/F (L/h) 30 mg (N=17) 691 (53) 2,886 (47) 12.8 (48) 60 …”; Omeprazole, “disease classified as Child-Pugh Class A (n=3), B (n=4) and C (n=1), the bioavailability increased to approximately …”
Generics: dexlansoprazole since 2017; omeprazole since 2002 (Drugs@FDA).
| Dexlansoprazole | Omeprazole | |
|---|---|---|
| Labeled for | Acid reflux and ulcers | Acid reflux and ulcers |
| Pharmacologic class | Proton Pump Inhibitor | Proton Pump Inhibitor |
| How it works (label) | Dexlansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the (H + , K + )-ATPase at the secretory surface of the gastric parietal cell. | Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H + /K + ATPase enzyme system at the secretory surface of the gastric parietal … |
| Half-life (label) | NT Once Daily for 7 Days Dose C max (ng/mL) AUC tau (ng∙h/mL) CL/F (L/h) 30 mg (N=17) 691 (53) 2,886 (47) 12.8 (48) 60 mg (N=18) 1,136 (51) 5,120 (58) 15.3 (49) Age: Geriatric Population The terminal elimination … | disease classified as Child-Pugh Class A (n=3), B (n=4) and C (n=1), the bioavailability increased to approximately 100% compared to healthy subjects, reflecting decreased first-pass effect, and the plasma half-life of … |
| Earliest approval on file (Drugs@FDA) | January 30, 2009 | September 14, 1989 |
| First generic approved | April 19, 2017 | November 1, 2002 |
| Generic labelers (NDC) | 9 labelers | 118 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $3.71 per capsule (Dexlansoprazole DR 60 mg capsule) | $0.0295 per capsule (Omeprazole DR 20 mg capsule) |
| 12-month price change | -18% | -7% |
| Boxed warning | No | No |
| Shortage now | No current entry | A presentation being discontinued |
| Recalls recorded | 0 | 7 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 41,466 | 446,179 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to dexlansoprazole
- every medicine labeled for the same conditions